Stock in Focus: Keep an eye on these 3 pharma stocks today, know what updates have come related to them?

News Topical, Digital Desk : Stock in Focus: Three pharma stocks will be on investors' radar on Wednesday, December 24th: Ajanta Pharma Ltd., Zydus Lifesciences Ltd., and Emcure Pharma Ltd. Of these three, Ajanta Pharma and Zydus Lifesciences have entered into licensing deals, while a unit of Emcure Pharma has received a special inspection report from the US drug regulator.

Ajanta
Pharma has entered into an in-licensing agreement with Biocon Ltd. for Semaglutide, a GLP-1 receptor agonist. Under this agreement, Biocon will supply Semaglutide, which Ajanta Pharma will market exclusively in 23 countries across Central Asia, Africa, and the Middle East, and semi-exclusively in three countries.

Semaglutide is used to improve blood sugar control in adults. According to the company, its product patent expires in March 2026 in most markets. Following regulatory approval, its commercial launch is planned for late 2026 or early 2027.

Zydus Lifesciences
has partnered with Swiss biopharmaceutical company Bioeq AG for the licensing, supply, and commercialization of NUFYMCO in the United States. NUFYMCO is an interchangeable biosimilar of Lucentis (ranibizumab). The company's wholly-owned subsidiary Zydus Lifesciences Global FZE will market it in the US, while Bioeq will handle its development, manufacturing, regulatory registration, and supply. NUFYMCO is a vascular endothelial growth factor (VEGF) inhibitor, which was approved by the US drug regulator on December 18. Ranibizumab is used in the treatment of age-related eye disease (neovascular age-related macular degeneration) and diabetic macular edema. 

Emcure Pharma Emcure Pharma has received an Establishment Inspection Report (EIR) from the US drug regulator for its Gujarat-based unit, which has been given a 'No Action Indicated' (NAI) classification. The US Food and Drug Administration inspected the plant located in Kadu village of Surendranagar district between October 6 and 10, 2025. The company stated that the inspection was completed without any observations, indicating regulatory compliance. NAI means that no objectionable conditions were found during the inspection and no regulatory or enforcement action is required. 

Stock Performance In the previous session, Ajanta Pharma shares closed 1% lower, while Zydus Lifesciences and Emcure Pharma shares closed with gains of 1.2% and 3.4%, respectively.

Read More: PM Kisan Yojana: Farmers will be in for a treat next month, but these farmers won't receive any money; are you included